SARS-CoV-2 vaccine and increased myocarditis mortality risk: A population based comparative study in Japan
View ORCID ProfileSintaroo Watanabe, View ORCID ProfileRokuro Hama
doi: https://doi.org/10.1101/2022.10.13.22281036
Sintaroo Watanabe
1Japan Marine United Corporation, Kure Shipyard, Kure, Japan
MD, PhDRokuro Hama
2Non-profit Organization “Japan Institute of Pharmacovigilance (Med Check)”, Osaka, Japan
MDData Availability
All data produced in the present study are available upon reasonable request to the authors.
Posted December 22, 2022.
SARS-CoV-2 vaccine and increased myocarditis mortality risk: A population based comparative study in Japan
Sintaroo Watanabe, Rokuro Hama
medRxiv 2022.10.13.22281036; doi: https://doi.org/10.1101/2022.10.13.22281036
Subject Area
Subject Areas
- Addiction Medicine (405)
- Allergy and Immunology (714)
- Anesthesia (209)
- Cardiovascular Medicine (2986)
- Dermatology (254)
- Emergency Medicine (446)
- Epidemiology (12848)
- Forensic Medicine (12)
- Gastroenterology (839)
- Genetic and Genomic Medicine (4652)
- Geriatric Medicine (428)
- Health Economics (735)
- Health Informatics (2960)
- Health Policy (1076)
- Hematology (394)
- HIV/AIDS (938)
- Medical Education (430)
- Medical Ethics (116)
- Nephrology (478)
- Neurology (4441)
- Nursing (239)
- Nutrition (653)
- Oncology (2310)
- Ophthalmology (655)
- Orthopedics (260)
- Otolaryngology (328)
- Pain Medicine (286)
- Palliative Medicine (85)
- Pathology (504)
- Pediatrics (1205)
- Primary Care Research (506)
- Public and Global Health (7039)
- Radiology and Imaging (1557)
- Respiratory Medicine (927)
- Rheumatology (447)
- Sports Medicine (387)
- Surgery (494)
- Toxicology (60)
- Transplantation (213)
- Urology (186)